NCT00041496View on ClinicalTrials.gov

Prevention Of Recurrence Of Atrial Fibrillation

PHASE2CompletedINTERVENTIONAL

Enrollment

520

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

December 31, 2003

Study Completion Date

December 31, 2003

Conditions

Fibrillation, Atrial

Interventions

DRUG

SB-207266

White, oval, biconvex tablets containing either 10mg, 25mg or 40mg

OTHER

Placebo

Placebo to match SB-207266

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00041496 - Prevention Of Recurrence Of Atrial Fibrillation | Biotech Hunter | Biotech Hunter